Treatment Preferences in Adults with Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines: Insights from CHOICE-CSU 2 Study
Author(s)
Shyam Joshi, MD1, Zhiqiang Song, MD2, Qiquan Chen, MD2, Cristina Constantinescu, MA3, panagiotis Orfanos, Ph.D.4, Ravneet Kaur Kohli, M.Pharm.5, Dhaval Patil, MS, B. Pharm6, Mondher Mtibaa, M.Sc.7, XIAOXIAO REN, M. Sc.8, Wanjie Guo, M.Sc.8, Alexandros Epameinondas Chrysos, Ph.D.9, Maike Mueller, Ph.D.10, Jana Kunder, B.Sc.10, Lucia Casoli, Ph.D.11, Aad Wissink, M.Sc.12, Paul Yamauchi, MD, Ph.D.13.
1Section of Allergy and Immunology, Oregon Health & Science University, Portland, OR, USA, 2The Southwest hospital of AMU, Chongqing, China, 3Ipsos, Basel, Switzerland, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Healthcare Private Limited, Hyderabad, India, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma Canada Inc., Montreal, QC, Canada, 8Novartis Pharma Co., Ltd., Beijing, China, 9Novartis Pharmaceuticals UK Limited, London, United Kingdom, 10Novartis Pharma GmbH, Nuremberg, Germany, 11Novartis Farma S.p.A., Milan, Italy, 12Novartis Pharma NL, Amsterdam, Netherlands, 13Dermatology Institute & Skin Care Center, Inc. and Clinical Science Institute, Santa Monica, CA, USA.
1Section of Allergy and Immunology, Oregon Health & Science University, Portland, OR, USA, 2The Southwest hospital of AMU, Chongqing, China, 3Ipsos, Basel, Switzerland, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Healthcare Private Limited, Hyderabad, India, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma Canada Inc., Montreal, QC, Canada, 8Novartis Pharma Co., Ltd., Beijing, China, 9Novartis Pharmaceuticals UK Limited, London, United Kingdom, 10Novartis Pharma GmbH, Nuremberg, Germany, 11Novartis Farma S.p.A., Milan, Italy, 12Novartis Pharma NL, Amsterdam, Netherlands, 13Dermatology Institute & Skin Care Center, Inc. and Clinical Science Institute, Santa Monica, CA, USA.
Presentation Documents
OBJECTIVES: Chronic spontaneous urticaria (CSU) is characterized by unpredictable, itch, hives with or without angioedema lasting over six weeks without external triggers. With the development of novel therapies, understanding patient preferences for attributes, such as efficacy, safety, and mode of administration, is critical. The CHOICE-CSU 2 study evaluated treatment preferences among adult patients with CSU inadequately controlled by H1- antihistamines.
METHODS: A global quantitative online survey was conducted among adult patients with CSU in the US, Canada, the UK, Germany, Italy, the Netherlands, and China, who were inadequately controlled by H1-antihistamines (Urticaria Control Test 7 [UCT] < 12). Participants were recruited via patient panels, advocacy groups, social media, and specialist referrals. The relative importance of treatment attributes and preference shares between hypothetical treatment profiles were identified using a Maximum Different Scaling Exercise and a Discrete Choice Experiment, respectively. Key attributes assessed included urticaria control, speed of treatment effect, impact on quality of life (QoL), sleep improvement, swelling reduction, mode of administration, side effects, and injection site reactions. Sensitivity analysis with scenarios of parity in efficacy were conducted to assess robustness of the results.
RESULTS: The interim analysis included 545 patients with CSU (56% women, mean age [standard deviation]: 39 [9] years). Based on patient preferences, the top five prioritized attributes were the impact of urticaria on QoL (71.1%), well-controlled urticaria (70.4%), side effects (68.7%), fast treatment effect (58.5%) and effect on swelling (39.8%). When attributes were evaluated using comparable clinical trial data, the majority of patients preferred oral treatment over injectable. Scenarios assuming parity in efficacy consistently indicated a stronger preference for oral treatments.
CONCLUSIONS: Patients prefer oral CSU treatments over injectables when efficacy and safety are comparable. The most important attributes patients consider when choosing a therapy are those that provide fast treatment effect and greatest improvement in QoL.
METHODS: A global quantitative online survey was conducted among adult patients with CSU in the US, Canada, the UK, Germany, Italy, the Netherlands, and China, who were inadequately controlled by H1-antihistamines (Urticaria Control Test 7 [UCT] < 12). Participants were recruited via patient panels, advocacy groups, social media, and specialist referrals. The relative importance of treatment attributes and preference shares between hypothetical treatment profiles were identified using a Maximum Different Scaling Exercise and a Discrete Choice Experiment, respectively. Key attributes assessed included urticaria control, speed of treatment effect, impact on quality of life (QoL), sleep improvement, swelling reduction, mode of administration, side effects, and injection site reactions. Sensitivity analysis with scenarios of parity in efficacy were conducted to assess robustness of the results.
RESULTS: The interim analysis included 545 patients with CSU (56% women, mean age [standard deviation]: 39 [9] years). Based on patient preferences, the top five prioritized attributes were the impact of urticaria on QoL (71.1%), well-controlled urticaria (70.4%), side effects (68.7%), fast treatment effect (58.5%) and effect on swelling (39.8%). When attributes were evaluated using comparable clinical trial data, the majority of patients preferred oral treatment over injectable. Scenarios assuming parity in efficacy consistently indicated a stronger preference for oral treatments.
CONCLUSIONS: Patients prefer oral CSU treatments over injectables when efficacy and safety are comparable. The most important attributes patients consider when choosing a therapy are those that provide fast treatment effect and greatest improvement in QoL.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR195
Topic
Patient-Centered Research
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)